The purpose of this study is to determine whether Cytokine induced killer cells combined chemotherapy is more effective in the treatment of advanced Pancreatic Cancer.
Pancreatic cancer is a devastating malignant disease with a median survival of 3-6 months and a 5-year survival rate of less than 5%. It is necessary to explore more treatment mode to pancreatic cancer especially advanced stage patients. This study is a prospective, randomized, open, single center phase II study. The investigators try to evaluate the efficacy and safety of this treatment mode.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
13
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Zhengzhou, Henan, China
Overall Survival
Time frame: From the date of randomization to the date of death from any cause up to 36 months
Progression Free Survival
Time frame: From the date of randomization to the date of first documented progression up to 24 months
Quality of life assessed by Questionnaire
Time frame: one year by questionnaire
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.